DBV Technologies and BIOPROJET Enter Into Distribution Agreement For Diallertest® Milk. DBV Technologies strengthens its distribution network for leading cow’s milk allergy paediatric diagnostic
Paris, France – 12 October 2009 – DBV Technologies, a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, announced today that it has signed a distribution agreement with BIOPROJET pharma for DBV’s Cow’s Milk protein allergy diagnostic, Diallertest® Milk. Under the terms of the agreement, BIOPROJET Pharma will promote and distribute Diallertest® Milk in France.
BIOPROJET pharma, a French paediatric focused pharmaceutical company, markets a number of products in France including Tiorfan® (a leading anti-diarrheal drug) Fanomer® (a nasal spray for children) and Fanolyte® (an oral rehydration solution). Since 2002, BIOPROJET Pharma has extended its distribution networks to include major European and overseas markets.
CNIL number: 1544201 v 0
DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83
SIRET: 441772522 00013
Executive editor: Pierre-Henri Benhamou
Hosting service: OVH www.ovh.com
Design : l’enchanteur www.lenchanteur.com